DrugPatentWatch Database Preview
Drugs in Development Information for Staurosporine
What is the development status for investigational drug Staurosporine?
Staurosporine is an investigational drug.
There have been 29 clinical trials for Staurosporine.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), University Health Network, Toronto, and Memorial Sloan Kettering Cancer Center.
There are two US patents protecting this investigational drug and twenty international patents.
Summary for Staurosporine
| US Patents | 2,159 |
| International Patents | 20,843 |
| US Patent Applications | 4,643 |
| WIPO Patent Applications | 2,114 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 2 (2017-12-01) |
| Vendors | 35 |
Recent Clinical Trials for Staurosporine
| Title | Sponsor | Phase |
|---|---|---|
| Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | National Cancer Institute (NCI) | Phase 2/Phase 3 |
| Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | National Cancer Institute (NCI) | Phase 2 |
| Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | Stanford University | Phase 2 |
Clinical Trial Summary for Staurosporine
Top disease conditions for Staurosporine
Top clinical trial sponsors for Staurosporine
US Patents for Staurosporine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Staurosporine | Start Trial | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | Start Trial |
| Staurosporine | Start Trial | Pyrazol-3-ones that activate pro-apoptotic BAX | Dana-Farber Cancer Institute, Inc. (Boston, MA) | Start Trial |
| Staurosporine | Start Trial | Tapered looped suture | Covidien LP (Mansfield, MA) | Start Trial |
| Staurosporine | Start Trial | Compositions and methods for inhibiting intimal hyperplasia | Start Trial | |
| Staurosporine | Start Trial | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III | Frequency Therapeutics, Inc. (Woburn, MA) | Start Trial |
| Staurosporine | Start Trial | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences, Inc. (Foster City, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Staurosporine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Staurosporine | World Intellectual Property Organization (WIPO) | 2015148714 | 2034-03-25 | Start Trial |
| Staurosporine | Australia | 2012322660 | 2031-10-11 | Start Trial |
| Staurosporine | Australia | 2017228527 | 2031-10-11 | Start Trial |
| Staurosporine | Canada | 2851788 | 2031-10-11 | Start Trial |
| Staurosporine | European Patent Office | 2766355 | 2031-10-11 | Start Trial |
| Staurosporine | World Intellectual Property Organization (WIPO) | 2013055949 | 2031-10-11 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
